Edwards Lifesciences’ SAPIEN M3 becomes first FDA-approved transseptal mitral valve replacement
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The opening of our 1000th pharmacy in Karnataka marks an important step
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Subscribe To Our Newsletter & Stay Updated